Amgen, a California-based biotechnology firm, has collaborated with Syapse, developer of a precision medicine software platform, to develop observational research analytics to evaluate treatment outcomes for areas of unmet need in oncology. The collaboration will recognize existing patients within the Syapse Learning Health Network that could be eligible for Amgen-supported clinical trials and looking for bringing these trials to community health system sites.
With this partnership, physicians and researchers will get opportunities within Syapse Network to obtain access to analytics, real-world evidence-based insights, and collaborative research opportunities. On this move, Amgen Senior Vice President of Strategy, Commercialization and Innovation Mike Nohaile said that “As cancer remains one of the leading causes of death around the world, emerging software, and data analytic tools are creating exciting opportunities to more rapidly developing and deliver targeted treatment options to patients.”
Nohaile further added that “Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care.” As part of the announcement, Amgen will also work with Syapse to create real-world evidence standards to support the acceleration of therapies to market. Seated in San Francisco, California, Syapse works with health systems to execute precision medicine programs across their organizations, allowing oncologists to deliver personalized care to every patient who needs it.